ADAP Stock Risk & Deep Value Analysis
Adaptimmune Therapeutics PLC
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About ADAP Stock
We analyzed Adaptimmune Therapeutics PLC using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ADAP through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is ADAP Stock?
Overall Risk
Aggressive
Financial Risk
Very High
Market Risk
High
Competitive Risk
High
Execution Risk
High
Regulatory Risk
Medium
What Are the Red Flags for ADAP?
- ⚠
Failure to secure immediate financing, leading to bankruptcy or liquidation
- ⚠
Delisting from NASDAQ due to low share price and/or market cap
- ⚠
Disappointing clinical trial results for pipeline candidates
- ⚠
Increased competition in the TCR-T cell therapy space
- ⚠
Further commercialization setbacks for Kimmtrak
Unlock ADAP Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Adaptimmune Therapeutics PLC (ADAP) Do?
Market Cap
$42.41M
Sector
Healthcare
Industry
Biotechnology
Employees
506
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Visit Adaptimmune Therapeutics PLC WebsiteIs ADAP Stock Undervalued?
Unlock the full AI analysis for ADAP
Get the complete DVR score, risk analysis, and more
Does ADAP Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Eroding
Moat Sources
1 Identified
The scientific moat derived from its patented platform and FDA approval is significant *in principle*, but its practical durability is severely undermined by the company's critical financial position. Without immediate and substantial funding, the company's ability to maintain and leverage this moat is highly questionable and could dissipate rapidly.
Moat Erosion Risks
- •Imminent insolvency leading to cessation of operations
- •Inability to fund further clinical development or commercial expansion
- •Emergence of superior or more commercially successful competing cell therapies
- •Loss of key scientific talent due to financial uncertainty
ADAP Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive ADAP Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Cash Runway Expiration: Critical update expected by end of Q1 2026 (March 31, 2026)
- •Potential announcement of strategic financing or partnership (highly unlikely but would be a re-rating event)
- •Any regulatory update on afami-cel or other pipeline candidates
Medium-Term (6-18 months)
- •Further clinical data for pipeline programs (assuming funding is secured to continue trials)
- •Potential for expanded commercialization efforts of Kimmtrak in other regions (conditional on financial viability)
- •Resolution of delisting concerns (if addressed by a reverse stock split or regaining compliance)
Long-Term (18+ months)
- •Broad adoption of SPEAR T-cell platform for multiple solid tumors
- •Successful development and commercialization of new cell therapies, establishing market leadership
- •Strategic acquisition by a larger pharmaceutical company for its platform technology
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ADAP?
- ✓
Any official announcement of significant, non-dilutive financing or strategic partnership (positive signal)
- ✓
Positive clinical data readouts from pipeline programs (positive, but secondary to funding)
- ✓
Any official communication regarding potential delisting or bankruptcy proceedings (negative signal)
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ADAP (Adaptimmune Therapeutics PLC) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
